Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Critical Therapeutics seeks approval for new Zyflo formulation
The new formulation only needs to be taken twice a day, whereas Zyflo, the currently marketed version of zileuton, has the drawback of requiring dosing four times a
The new formulation only needs to be taken twice a day, whereas Zyflo, the currently marketed version of zileuton, has the drawback of requiring dosing four times a
The phase IIb trial results are expected to be available towards the end of 2006 following completion of the three month follow-up period. “Patient enrolment into stroke trials
To evaluate the driving safety performance of a small group of young adults with ADHD taking medication or placebo, the researchers conducted a pilot study using a driving
Factive-5 will be marketed in the territory by Pfizer Mexico which sublicensed the rights to develop and commercialize Factive in that country from Oscient in February of this
The AZD-103 compound is a potentially disease-modifying therapeutic drug candidate for the treatment of Alzheimer’s disease. According to the company, this unique class of drug candidates may provide
The prevention of preterm birth would be a new indication for Prochieve which is currently approved and commercially available to treat infertility and secondary amenorrhea. This large-scale global
The trial, which is currently ongoing at several sites in Italy, will examine IR103, a second-generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended
The open-label, dose-escalation trial is designed to assess the safety and maximum-tolerated dose of Oncaspar in combination with Gemzar in patients with these cancers. Oncaspar was initially approved
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation
The phase I dose-escalation trial is the first human study with MDX-1106 (also known as ONO-4538), a fully human anti-PD-1 antibody for the treatment of cancer, and is